Biotech Values

[stockbettor]

antisoma received $75M upfront from NVS

It ran a successful randomized PII trial of its vascular disrupting agent ASA404 prior to striking the deal with NVS in 2007. If I remember correctly, antisoma had less than 2 months cash at time of deal. Royalties were undisclosed, but NVS did grant it a co-marketing option in the US if the VDA was approved. The VDA failed its PIII trials in NSCLC. Although it had other drugs in the clinic at the time of the PIII failures, antisoma now appears to have ceased active business operations.

http://www.antisoma.com/archive/reports/ar2007.pdf